What atorvastatin regulatory approvals happened in 2023–2024 (FDA and EMA)?
You can track specific FDA and EMA “approval” events (new strengths, new formulations like tablets vs. chewables, new fixed-dose combinations, and new indications) by checking the drug’s most recent regulatory actions in each authority’s database. The provided information here doesn’t include the underlying approval list for 2023–2024, so I can’t accurately name which particular atorvastatin products or label indications were authorized in those years without risking errors.
If you share whether you mean:
- atorvastatin as the active ingredient (all generics included), or
- a specific brand/generic product (for example, Lipitor or a particular sponsor’s NDA/ANDA),
- or whether you mean approvals/labeling changes vs. manufacturing/formulation-only changes,
…I can narrow it to the exact regulatory actions.
Were any “new formulations” for atorvastatin approved in 2023–2024?
Atorvastatin approvals over short windows are often formulation- or product-specific, such as new tablet strengths, alternative dosage forms, or changes to dissolution/biopharmaceutic properties. These typically show up as:
- brand-label supplements in the US (NDA supplement approvals), and/or
- new marketing authorisation variations in the EU (changes to product characteristics and sometimes updated product information).
Because “new formulation” is ambiguous without the exact product(s), the safest way to verify is to search the EMA product page (for the relevant marketing authorisation) and the FDA Orange Book for the same time period, then cross-check whether the label changed (new indications, dosing, warnings) versus only formulation/manufacturing changes.
Did atorvastatin get new indications in 2023–2024?
Label changes that add new indications are usually significant and would be reflected in FDA-approved labeling and EMA product information updates for the relevant marketing authorisation(s). In many years, atorvastatin’s core indications (e.g., hypercholesterolemia, mixed dyslipidemia, and cardiovascular risk-related uses) generally remain stable, while updates may instead focus on:
- pediatric or special-population dosing language,
- safety/monitoring updates,
- or expanded use in combination regimens (often tied to specific combination products).
To name “new indications in 2023–2024,” I need either the specific product and applicant/sponsor or permission to interpret “atorvastatin approvals” broadly across all generic ANDAs/variations—which would produce a very large set and still not tell you which were label-level indication changes.
How to verify the exact 2023–2024 FDA and EMA approvals quickly (what to search)
If you want the precise answer for “2023–2024 approvals,” these are the most reliable starting points:
- FDA: the Orange Book and Drugs@FDA for the relevant atorvastatin sponsor(s) to identify NDA supplements/ANDA approvals and the “approval date,” then check whether the label (indications section) changed.
- EMA: the EMA human medicines database for the marketing authorisation(s) and then review “EPAR” or “product information” history/variation dates and whether indications were updated.
Patent and exclusivity context (useful for “new” atorvastatin products)
If part of your goal is understanding whether “new” atorvastatin formulations were enabled by patent or exclusivity timing, DrugPatentWatch.com can help map patent estates and exclusivity events for specific products and sponsors. See DrugPatentWatch for atorvastatin-related patent tracking here: https://www.drugpatentwatch.com/ [1].
What I need from you to produce the exact 2023–2024 approval list
Reply with one of these so I can give a precise, cited answer:
1) Which formulation(s) you care about (e.g., Lipitor brand vs. a particular generic manufacturer; tablets vs. chewables; any fixed-dose combination product), or
2) Whether you want “any regulatory approval” (including formulation/manufacturing and label supplements) or only “new indications.”
Once you confirm, I’ll provide a targeted timeline of FDA and EMA actions for 2023–2024 and state what changed (formulation, dosing, and whether an indication was added).
---
Sources
[1] https://www.drugpatentwatch.com/